

Bonaventure Equity Announces the Appointment of Robert J. Toth, Jr. to the Position of Scientific Operating Partner

Seasoned biotechnology executive joins BVE's cannabis and psilocybin life sciences fund.

RALEIGH, NORTH CAROLINA, UNITED STATES, April 11, 2022

/EINPresswire.com/ -- [Bonaventure Equity](#), LLC ("BVE"), a cannabis and psilocybin life sciences venture capital firm, is pleased to announce [Robert J. Toth, Jr.](#) has joined BVE as a Scientific Operating Partner for its second fund,

BVE Select Fund II, L.P.. A seasoned executive and advisor, Mr. Toth has two decades' experience within the biotechnology industry, adding significantly to BVE's industry depth and expertise.



BONAVENTURE
EQUITY, LLC

www.bve.vc

"We are incredibly pleased to have such an accomplished individual join the BVE team," said BVE

“

We believe there is no one more qualified than Rob to critically evaluate and help build long term value in the innovative life sciences companies we are investing in.”

Ross O'Brien

Founder and Managing Partner, Ross O'Brien. He continued, "Rob's CV reads like a scientific operating partner wish-list. He has spent the better part of his career in the financial sector with an emphasis on biotech. As a former hedge fund portfolio manager and senior equity research analyst, coupled with a background in biotech commercialization and molecular biological research, we believe there is no one more qualified than Rob to critically evaluate and help build long term value in the innovative life sciences companies we are investing in."

Mr. Toth currently serves on the board of directors for Kintara Pharmaceuticals, Inc (2013-present), a NASDAQ-listed biotechnology company, and is also a Limited Partner at Northern Waters, LLC (2005-present). His previous roles include Consulting Analyst for Narragansett Asset Management (2004-2005), Senior Portfolio Manager for EGM Capital's Medical Technology hedge fund (2001-2003), Senior Vice President and Biotechnology Analyst for Prudential Securities

(1999-2001), Senior Biotechnology Analyst for Vector Securities International (1996-1999), business development and research roles for Connectics Corporation (1993-1996), intellectual property assessment and technology out-licensing for University of Washington's Office of Technology Transfer (1992-1993), and manufacturing, research and clinical roles for Genentech, Inc. (1987-1991). In 1999, he was named to the Wall Street Journal's All-Star List for stock picking. Mr. Toth holds an MBA from the University of Washington and dual Bachelor of Science degrees in Biological Sciences and Biochemistry from California Polytechnic State University, San Luis Obispo.

To learn more about Bonaventure Equity, please visit www.bve.vc.

Ross O'Brien
Bonaventure Equity, LLC
+1 561-308-3293

[email us here](#)

Visit us on social media:

[Facebook](#)

[Twitter](#)

[LinkedIn](#)

This press release can be viewed online at: <https://www.einpresswire.com/article/567881491>

EIN Presswire's priority is source transparency. We do not allow opaque clients, and our editors try to be careful about weeding out false and misleading content. As a user, if you see something we have missed, please do bring it to our attention. Your help is welcome. EIN Presswire, Everyone's Internet News Presswire™, tries to define some of the boundaries that are reasonable in today's world. Please see our Editorial Guidelines for more information.

© 1995-2022 IPD Group, Inc. All Right Reserved.